"The results of this study demonstrate that integrating deCODE MI(TM) into the standard list of risk factors now used to assess CHD risk can improve the prediction of risk of future cardiac events. This provides physicians with a more accurate basis upon which to target cholesterol levels for individual patients and thus for tailoring statin use, in addition to addressing other risk factors such as obesity, smoking and hypertension. The study is all the more important because deCODE MI is available to clinicians today through our CLIA-registered laboratory," said Dr. Kari Stefansson, M.D., Dr. Med., CEO of deCODE.
About deCODE MI(TM)
deCODE MI(TM) is a DNA-based test for identifying individuals at increased risk for myocardial infarction (MI). It is a reference laboratory test which detects versions of SNPs in the CDKN2A/2B gene region on chromosome 9p21. deCODE genetics has reported, based on studies of thousands of patients in multiple cohorts from the US and Europe, that individuals who are positive for this test are at approximately 1.6-times higher risk of MI, and at approximately twice the risk of early-onset MI (before age 50 in men and age 60 in women) than are those without the genetic risk variants. About 20% of people of European descent are positive for this test. deCODE's findings have been confirmed in multiple studies in the US, Canada, United Kingdom and Europe.
How to order deCODE MI(TM)
Additional information and physician order forms for deCODE MI(TM) can
be found at http://www.decodediagnostics.com. The price of the test is $200
dollars and deCODE facilitates reimbursement from commercial insurers.
Testing is performed in deCODE's CLIA-registered laboratory, which has
analyzed the genomes of hundreds of thousands of p
|SOURCE deCODE genetics|
Copyright©2008 PR Newswire.
All rights reserved